Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-788 in Japanese Non-Small Cell Lung Cancer Patients
jRCT2080224519Phase 2Completed
- Sponsor
- Takeda
- Start
- Jan 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of mobocertinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Takeda. Primary endpoints: Safety and tolerability of TAK-788 and Recommended Phase 2 dose determination. Started Jan 2019; status: completed.
02
Drugs
mobocertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2080224519.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224519.